Management of Hepatitis C Virus-related Mixed Cryoglobulinemia

American Journal of Medicine

Volumn 123, Issue 5, 2010, Pages 400-408

  Iannuzzella, Francesco ^a   Vaglio, Augusto ^a   Garini, Giovanni ^a  

^a UNIVERSITY OF PARMA MEDICAL SCHOOL   (Italy)

Author keywords

Cryoglobulinemia; Hepatitis C virus (HCV); Interferon; Ribavirin; Rituximab

Indexed keywords

ALBINTERFERON ALPHA2B; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; AZATHIOPRINE; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID; CPG 10101; CRYOGLOBULIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC AGENT; DULOXETINE; ILOPROST; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PREDNISONE; PREGABALIN; RIBAVIRIN; RITUXIMAB; TARIBAVIRIN; TELAPREVIR; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR INHIBITOR;

ALOPECIA; ANEMIA; ARTHRALGIA; AUTOIMMUNE THYROIDITIS; B LYMPHOCYTE; BRONCHOSPASM; CELL EXPANSION; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; CRYOGLOBULINEMIA; DEPRESSION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; FATIGUE; FEVER; FLU LIKE SYNDROME; GENETIC POLYMORPHISM; GLOMERULONEPHRITIS; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NAUSEA; NECROTIZING ARTERITIS; NEUROPATHIC PAIN; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; PURPURA; REVIEW; SKIN ULCER; THROMBOCYTOPENIA; URTICARIA; VASCULITIS; VOMITING; WEAKNESS;

CRYOGLOBULINEMIA; HEPATITIS C; HUMANS; VASCULITIS;

EID: 77950612337     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.09.038     Document Type: Review

References (95)

1. Wintrobe M.M., and Buell M.V. Hypoproteinemia associated with multiple myeloma. Bull Johns Hopkins Hosp 52 (1933) 156-165
2. Brouet J.C., Clauvel J.P., Danon F., et al. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 57 (1974) 775-788
3. Lospalluto J., Dorward B., Miller Jr. W., and Ziff M. Cryoglobulinemia based on interaction between a gamma macroglobulin and 7S gamma globulin. Am J Med 32 (1962) 142-145
4. Ferri C., Zignego A.L., and Pileri S.A. Cryoglobulins. J Clin Pathol 55 (2002) 4-13
5. Lamprecht P., Gause A., and Gross W.L. Cryoglobulinemic vasculitis. Arthritis Rheum 42 (1999) 2507-2516
6. Pascual M., Perrin L., Giostra E., and Schifferli J. Hepatitis C virus in patients with cryoglobulinemia type II. J Infect Dis 162 (1990) 569-570
7. Casato M., Pucillo L.P., Lagana B., et al. Cryoglobulinemia and hepatitis C virus. Lancet 337 (1991) 1047-1048
8. Disdier P., Harle J.R., and Weiller P.J. Cryoglobulinemia and hepatitis C virus infection. Lancet 338 (1991) 1151-1152
9. Agnello V., Chung R.T., and Kaplan L.M. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 327 (1992) 1490-1495
10. Monti G., Galli M., Invernizzi F., et al. Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. QJM 88 (1995) 115-126
11. Cacoub P., Musset L., Lunel-Fabiani F., et al. Hepatitis C virus and essential mixed cryoglobulinemia. Br J Rheumatol 32 (1993) 685-692
12. Mayo M.J. Extrahepatic manifestations of hepatitis C infection. Am J Med Sci 325 (2003) 135-148
13. Gorevic P.D., and Frangione B. Mixed cryoglobulinemia crossreactive idiotypes: Implications for the relationship of MC to rheumatic and lymphoproliferative diseases. Semin Hematol 28 (1991) 79-94
14. Agnello V. The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection. Springer Semin Immunopathol 19 (1997) 111-129
15. Pileri P., Uematsu Y., Campagnoli S., et al. Binding of hepatitis C virus to CD81. Science 282 (1998) 938-941
16. Monti G., Pioltelli P., Saccardo F., et al. Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch Intern Med 165 (2005) 101-105
17. Kayali Z., Buckwold V.E., Zimmerman B., and Scmidt W.N. Hepatitis C, cryoglobulinemia, and cirrhosis: a meta-analysis. Hepatology 36 (2002) 978-985
18. Agnello V., and De Rosa F.G. Extrahepatic disease manifestations of HCV infection: some current issues. J Hepatol 40 (2004) 341-352
19. Sène D., Limal N., and Cacoub P. Hepatitis C virus-associated extrahepatic manifestations: a review. Metab Brain Dis 19 (2004) 357-381
20. Gorevich P.D., Kassab H.J., Levo Y., et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 69 (1980) 287-308
21. Meltzer M., and Franklin E.C. Cryoglobulinemia: a study of 29 patients. I. IgG and IgM cryoglobulins and factors affecting cryoprecipitability. Am J Med 40 (1966) 828-836
22. Ferri C., Sebastiani M., Giuggioli D., et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 33 (2004) 355-374
23. Agnello V., and Abel G. Localization of hepatitis C virus in cutaneous vasculitic lesions in patients with type II cryoglobulinemia. Arthritis Rheum 40 (1997) 2007-2015
24. Johnson R.J., Willson R., Yamabe H., et al. Renal manifestations of hepatitis C virus infection. Kidney Int 46 (1994) 1255-1263
25. Tarantino A., Campise M., Banfi G., et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 47 (1995) 618-623
26. D'Amico G. Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int 54 (1998) 650-671
27. Roccatello D., Fornasieri A., Giachino O., et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 49 (2007) 69-82
28. Smith K.D., and Alpers C.E. Pathogenic mechanism in membranoproliferative glomerulonephritis. Curr Opin Nephrol Hypertens 14 (2005) 396-403
29. Zaltron S., Puoti M., Liberini P., et al. High prevalence of peripheral neuropathy in hepatitis C virus infected patients with symptomatic and asymptomatic cryoglobulinemia. Ital J Gastroenterol Hepatol 30 (1998) 391-395
30. Apartis E., Leger J.-M., Musset L., et al. Peripheral neuropathy associated with essential mixed cryoglobulinaemia: a role for hepatitis C virus infection?. J Neurol Neurosurg Psychiatry 60 (1996) 661-666
31. Boukhris S., Magy L., Senga-mokono U., Loustaud-ratti V., and Vallat J.M. Polyneuropathy with demyelinating features in mixed cryoglobulinemia with hepatitis C virus infection. Eur J Neurol 13 (2006) 937-941
32. Alpa M., Ferrero B., Cavallo R., et al. Anti-neuronal antibodies in patients with HCV-related mixed cryoglobulinemia. Autoimmun Rev 8 (2008) 56-58
33. Lee Y.H., Ji J.D., Yeon J.E., et al. Cryoglobulinemia and rheumatic manifestations in patients with hepatitis C virus infection. Ann Rheum Dis 57 (1998) 728-731
34. Sene D., Ghillani-Dalbin P., Limal N., et al. Anti-cyclic citrullinated peptide antibodies in hepatitis C virus associated rheumatological manifestations and Sjögren's syndrome. Ann Rheum Dis 65 (2006) 394-397
35. Matsumori A., Ohashi N., Hasegawa K., et al. Hepatitis C virus infection and heart diseases: a multicenter study in Japan. Jpn Circ J 62 (1998) 389-391
36. Manganelli P., Salaffi F., Subiaco S., et al. Bronchoalveolar lavage in mixed cryoglobulinaemia associated with hepatitis C virus. Br J Rheumatol 35 (1996) 978-982
37. Ferri C., La Civita L., Fazzi P., et al. Interstitial lung fibrosis and rheumatic disorders in patients with hepatitis C virus infection. Br J Rheumatol 36 (1997) 360-365
38. Kallemuchikkal U., and Gorevic P.D. Evaluation of cryoglobulins. Arch Pathol Lab Med 123 (1999) 119-125
39. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 19 (2002) 1-46
40. Feld J.J., and Hoofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436 (2005) 967-972
41. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic C virus infection. N Engl J Med 347 (2002) 975-982
42. Hadziyannis S.J., Sette Jr. H., Morgan T.R., et al. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
43. Dienstag J.L., and McHutchison J.G. American Gastroenterological Association technical review on the management on hepatitis C. Gastroenterology 130 (2006) 231-264
44. Russo M.W., and Fried M.W. Side effects of therapy for chronic hepatitis C. Gastroenterology 124 (2003) 1711-1719
45. Casato M., Laganà B., Antonelli G., et al. Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia. Blood 78 (1991) 3142-3147
46. Ferri C., Marzo E., Longobardo G., et al. Interferon-α in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 81 (1993) 1132-1136
47. Mazzaro C., Pozzato G., Moretti M., et al. Long-term effects of alpha interferon therapy for type II mixed cryoglobulinemia. Haematologica 79 (1994) 342-349
48. Misiani R., Bellavita P., Fenili D., et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 330 (1994) 751-756
49. Mazzaro C., Franzin F., Tulissi P., et al. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy. Cancer 77 (1996) 2604-2613
50. Polzien F., Schott P., Mihm S., et al. Interferon-α treatment hepatitis C virus-associated mixed cryoglobulinemia. J Hepatol 27 (1997) 63-71
51. Donada C., Crucitti A., Donadon V., et al. Interferon-α and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia. Blood 92 (1998) 2983-2984
52. Cresta P., Musset L., Cacoub P., et al. Response to interferon α treatment and disappearance of cryoglobulinemia in patients infected by hepatitis C virus. Gut 45 (1999) 128-134
53. Zuckerman E., Keren D., Slobodin G., et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 27 (2000) 2172-2178
54. Garini G., Allegri L., Carnevali L., et al. Interferon-alfa in combination with ribavirin as initial treatment for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis. Am J Kidney Dis 38 (2001) E35-E39
55. Sabry A.A., Sobh M.A., Sheaashaa H.A., et al. Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy. Nephrol Dial Transplant 17 (2002) 1924-1930
56. Rossi P., Bertani T., Baio P., et al. Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy. Kidney Int 63 (2003) 2236-2241
57. Mazzaro C., Zorat F., Caizzi M., et al. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 42 (2005) 632-638
58. Saadoun D., Resche-Rigon M., Thibault V., et al. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum 54 (2006) 3696-3706
59. Boonyapisit K., and Katirji B. Severe exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon alpha: a case report and literature review. Muscle Nerve 6 (2002) 909-913
60. Otha S., Yokoyama H., Wada T., et al. Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy. Am J Kidney Dis 33 (1999) 1040-1048
61. Bruchfeld A., Lindahl K., Stahle L., et al. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 18 (2003) 1573-1580
62. Nelson D.R., Rustgi V., Balan V., et al. Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C. Clin Gastroenterol Hepatol 7 (2009) 212-218
63. Gish R.G., Arora S., Rajender Reddy K., et al. Virological response and safety outcomes in therapy-naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. J Hepatol 47 (2007) 51-59
64. De Francesco R., and Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 436 (2005) 953-960
65. Hézode C., Forestier N., Dusheiko G., et al., PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 360 (2009) 1839-1850
66. McHutchison J., Bacon B., Gordon S.C., et al. Relationships of HCV RNA responses to CPG, a TLR agonist, pharmacodynamics and patient characteristics. Hepatology 42 (2005) 249A
67. McHutchison J., Bacon B.R., Gordon S.C., et al. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 46 (2007) 1317-1318
68. Lamprecht P., Gause A., and Gross W.L. Cryoglobulinemic vasculitis. Arthritis Rheum 42 (1999) 2507-2516
69. Campise M., and Tarantino A. Glomerulonephritis in mixed cryoglobulinemia: what treatment?. Nephrol Dial Transplant 14 (1999) 281-283
70. Vassilopoulos D., and Calabrese L.H. Hepatitis C virus infection and vasculitis. Implications of antiviral and immunosuppressive therapies. Arthritis Rheum 46 (2002) 585-597
71. Koukoulaki M., and Jayne D.R. Mycophenolate mofetil in anti-neutrophil cytoplasm antobodies-associated systemic vasculitis. Nephron Clin Pract 102 (2006) 100-107
72. Ramos-Casals M., and Font J. Mycophenolate mofetil in patients with hepatitis C virus infection. Lupus 14 Suppl 1 (2005) S64-S72
73. Reed M.J., Alexander G.J., Thiru S., and Smith K.G. Hepatitis C-associated glomerulonephritis-a novel therapeutic approach. Nephrol Dial Transplant 16 (2001) 869-871
74. Bombardieri S., Ferri C., Paleologo G., et al. Prolonged plasma exchange in the treatment of renal involvement in essential mixed cryoglobulinemia. Int J Artif Organs 6 Suppl 1 (1983) S47-S50
75. Ramunni A., Lauletta G., Brescia P., et al. Double-filtration plasmapheresis in the treatment of leg ulcers in cryoglobulinemia. J Clin Apher 23 (2008) 118-122
76. Sansonno D., De Re V., Lauletta G., et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101 (2003) 3818-3826
77. Zaja F., De Vita S., Mazzaro C., et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101 (2003) 3827-3834
78. Saadoun D., Delluc A., Piette J.C., and Cacoub P. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol 20 (2008) 23-28
79. Lamprecht P., Lerin-Lozano C., Merz H., et al. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis 62 (2003) 1230-1233
80. Kazkaz H., and Isenberg D. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Curr Opin Pharmacol 4 (2004) 398-402
81. Roccatello D., Baldovino S., Rossi D., et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 19 (2004) 3054-3061
82. Ghijsels E., Lerut E., Vanrenterghem Y., and Kuypers D. Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure. Am J Kidney Dis 43 (2004) e34-e38
83. Koukoulaki M., Abeygunasekara S.C., Smith K.G.C., and Jayne D.R.W. Remission of refractory hepatitis C-negative cryoglobulinaemic vasculitis after rituximab and infliximab. Nephrol Dial Transplant 20 (2005) 213-216
84. Booth A., Harper L., Hammad T., et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 15 (2004) 717-721
85. Bartolucci P., Ramanoelina J., Cohen P., et al. Efficacy of the anti-TNF-α antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology 41 (2002) 1126-1132
86. Chandesris M.O., Gayet S., Schleinitz N., et al. Infliximab in the treatment of refractory vasculitis secondary to hepatitis C-associated mixed cryoglobulinemia. Rheumatology 43 (2004) 532-533
87. Galeazzi M., Bellisai F., Giannitti C., et al. Safety of cyclosporin A in HCV-infected patients. Ann N Y Acad Sci 1110 (2007) 544-549
88. Ferri C., Pietrogrande M., Cecchetti C., et al. Low-antigen-content diet in the treatment of mixed cryoglobulinemia patients. Am J Med 87 (1989) 519-524
89. Attal N., Cruccu G., Haanpää M., et al. EFNS guidlines on pharmacological treatment of neuropathic pain. Eur J Neurol 13 (2006) 153-169
90. Lo Gullo R., De Filippis L., Caliari A., and Bagnato G. Successful treatment of necrotizing vasculitic lesions after infusion of iloprost in a patient with cryoglobulinemia and chronic HCV infection. Clin Exp Rheumatol 23 (2005) 912-913
91. Monti G., Saccardo F., Rinaldi G., et al. Colchicine in the treatment of mixed cryoglobulinemia. Clin Exp Rheumatol 13 Suppl 13 (1995) S197-S199
92. Luqmani R.A., Exley A.R., Kitas G.D., and Bacon P.A. Disease assessment and management of the vasculitides. QJM 87 (1994) 671-678
93. Reinhold-Keller E., Kekow J., Schnabel A., et al. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum 37 (1994) 919-924
94. Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease. Guideline 2: treatment of HCV infection in patients with CKD. Kidney Int 73 Suppl 109 (2008) S20-S45
95. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 Suppl 1 (2002) S1-S266